Allogeneic Bone Marrow Transplantation in Multiple Myeloma

• Published in: The New England journal of medicine Vol. 325; no. 18; pp. 1267 - 1273
• Main Authors: Gahrton, Gösta, Tura, Sante, Ljungman, Per, Belanger, Coralie, Brandt, Lena, Cavo, Michele, Facon, Thierry, Granena, Alberto, Gore, Martin, Gratwohl, Alois, Löwenberg, Bob, Nikoskelainen, Jukka, Reiffers, Josy J, Samson, Diana, Verdonck, Leo, Volin, Liisa
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 31.10.1991
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Autografts; Biological and medical sciences; Bone marrow; Bone marrow transplantation; Bone marrow, stem cells transplantation. Graft versus host reaction; Cancer; Càncer; Diagnosis; Donors; Graft-versus-host reaction; Histocompatibility antigen HLA; Medical sciences; Medul·la òssia; Mielomatosi; Multiple myeloma; Myeloproliferative disorders; Remission; Statistical analysis; Stem cell transplantation; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation; Transplantation of organs; Trasplantament d'òrgans; Tumor cells; Human; Multiple; Treatment; Homograft; Bone marrow; Malignant hemopathy; Myeloma
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199110313251802

MULTIPLE myeloma is a fatal disorder with a median survival of about 36 months after conventional chemotherapy. 1 2 3 Even so, more than 50 percent of patients with multiple myeloma respond to first-line therapy, and some patients may even have a complete remission, defined as no detectable monoclonal immunoglobulin in the serum, no light chains in the urine, and no apparent myeloma cells in the bone marrow. Complete remission may occur after conventional intermittent therapy with melphalan plus prednisolone or with multidrug combination chemotherapy. More intensive chemotherapy seems to increase the fraction of patients entering complete remission, particularly if the treatment ablates . . .